Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relicaps Advance
- Development stage
- Unknown
- Lead developer
- Minskintercaps
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Relicaps Advance is a hepatoprotective combination pharmaceutical product developed by Minskintercaps. It is composed of essential phospholipids (300 mg) and a complex of vitamins, including thiamine (B1), riboflavin (B2), pyridoxine (B6), cyanocobalamin (B12), nicotinamide (PP), and tocopherol (E). The essential phospholipids are primarily composed of phosphatidylcholine, which integrates into the lipid layer of damaged hepatocyte membranes, thereby restoring their structural integrity and enzymatic activity. The B-group vitamins serve as coenzymes in protein, lipid, and carbohydrate metabolism, while vitamin E provides antioxidant protection against lipid peroxidation. Relicaps Advance is indicated for the treatment of various liver conditions, including chronic hepatitis, liver cirrhosis, fatty liver disease (steatosis), and toxic liver damage resulting from alcohol or drug use.
- Brand names
- Relicaps Advance
- Other names
- Relicaps Advance
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on Relicaps Advance.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Relicaps Advance.